Physician profile
Robert Martinez
NPI 1295826212
$2,287.55
in general payments reported to CMS, 2019-2025
24 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $150 · 2021: $318 · 2022: $359 · 2023: $474 · 2024: $506 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.05 | 2021-2025 | |
| Pfizer INC. | $364.16 | 2023-2025 | |
| Lundbeck LLC | $139.34 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $109.95 | 2025 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $99.23 | 2019-2020 | |
| Medtronic, INC. | $76.45 | 2022 | |
| Amgen INC. | $65.34 | 2019-2022 | |
| Harmony Biosciences LLC | $60.92 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $46.12 | 2020-2021 | |
| Allergan, INC. | $42.47 | 2020 | |
| Emd Serono, INC. | $40.62 | 2023-2024 | Mavenclad |
| Acadia Pharmaceuticals INC | $39.03 | 2022-2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $36.68 | 2020-2024 | Rexulti |
| Biogen, INC. | $36.33 | 2019-2021 | |
| Genzyme Corporation | $34.33 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $29.86 | 2022 | |
| Lilly USA, LLC | $27.41 | 2024 | Kisunla |
| Ucb, INC. | $24.23 | 2023 | |
| Ge Healthcare | $20.70 | 2025 | |
| Jazz Pharmaceuticals INC. | $20.35 | 2020 | |
| Csl Behring | $19.73 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.57 | 2022 | |
| Nevro Corp. | $14.84 | 2023 | Senza |
| E.R. Squibb & Sons, L.L.C. | $14.84 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.